🇺🇸 FDA
Pipeline program

SELPERCATINIB, Selpercatinib, Selpercatinib, SELPERCATINIB, Selpercatinib

LOXO-RET-18036

Phase 2 small_molecule active

Quick answer

SELPERCATINIB, Selpercatinib, Selpercatinib, SELPERCATINIB, Selpercatinib for Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors is a Phase 2 program (small_molecule) at Ology Bioservices Ireland LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
Ology Bioservices Ireland LTD
Indication
Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials